B Lymphocyte Subset Changes in Primary Membranous Nephropathy
| Author | Katayoun Hasanzadeh | en |
| Author | Fatemeh Pour-Reza-Gholi | en |
| Author | Narjes Soleimanifar | en |
| Author | Nooshin Dalili | en |
| Author | Mahboobeh Freidoon | en |
| Author | Bita Ansaripour | en |
| Author | Bahareh Mohebbi | en |
| Author | Mohammad Hossein Nicknam | en |
| Author | Sara Assadiasl | en |
| Orcid | Fatemeh Pour-Reza-Gholi [0000-0001-7534-8309] | en |
| Orcid | Narjes Soleimanifar [0000-0002-8886-2902] | en |
| Orcid | Nooshin Dalili [0000-0002-1618-0937] | en |
| Orcid | Mahboobeh Freidoon [0000-0002-0219-1344] | en |
| Orcid | Bahareh Mohebbi [0000-0002-7219-9923] | en |
| Orcid | Mohammad Hossein Nicknam [0000-0001-9132-1675] | en |
| Orcid | Sara Assadiasl [0000-0001-5244-3127] | en |
| Issued Date | 2019-11-30 | en |
| Abstract | Background: Primary membranous nephropathy (PMN) is an autoimmune disease affecting renal glomerulus, characterized by autoantibodies aggregation on podocytes and subsequent epithelial thickening. Therefore, rituximab, an anti-CD20 monoclonal antibody, is used to treat patients with the deteriorating condition. Objectives: Assuming that rituximab demolishes a considerable number of B-lymphocytes and causes transient immunodeficiency, we aimed to identify B cell subsets involved in PMN pathogenesis to facilitate specific targeting. Methods: Using flowcytometery, 25 PMN patients including 15 on standard treatment and 10 on standard treatment plus rituximab were enrolled to compare with healthy controls. Rituximab-receiving patients were studied before and two months after administration. Results: Neither total CD19+ nor memory B cell percentages showed significant differences between the study groups. However, the number of B regulatory cells (Breg) was lower in both standard-treatment and Rituximab-receiving patients than in controls. Moreover, the percentage of naïve/mature B cells dropped after standard treatment. Conclusions: PMN patients seem to possess an insufficient percentage of Breg cells, which are involved in immunomodulation. Furthermore, the standard-treatment group showed a reduced count of naïve/mature B cells, which constitute a substantial proportion of normal B lymphocytes population. | en |
| DOI | https://doi.org/10.5812/numonthly.96425 | en |
| Keyword | Glomerulonephritis | en |
| Keyword | Membranous Nephropathy | en |
| Keyword | B Lymphocyte Subsets | en |
| Keyword | Rituximab | en |
| Publisher | Brieflands | en |
| Title | B Lymphocyte Subset Changes in Primary Membranous Nephropathy | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- num-11-4-96425.pdf
- Size:
- 269.45 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF